Pharma & Biotech Global Week in Review 6 Oct 10 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Prezista (Darunavir) – US NIH becomes first patent holder to join UNITAID Medicines Patent Pool (IP Watch) (KEI)

Taxotere (Docetaxel) – US: District Court finds Sanofi’s Taxotere invalid: Aventis v Hospira (Patent Docs)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Update on the Indo-E.U. trade dispute before the WTO (Spicy IP)

Australia: Proceedings in other jurisdictions no excuse for delay: Wyeth v The Kennedy Institute of Rheumatology (Patentology)

EU: Positive opinions on Paediatric Investigation Plans (The SPC Blog)

EU: Guidelines for biosimilar antibodies in Europe due in November (Patent Docs)

Netherlands: Court of Appeal of The Hague dismisses request to suspend execution of judgment in first instance: Sandoz v Leo Pharmaceutical Products (EPLAW)

UK: New UK Office manual changes affect SPCs (The SPC Blog)

UK: Even more about HPV vaccines and SPCs: BL O/335/10 (The SPC Blog)

US: FDA planning to hold public hearing on biosimilar approval pathway (Patent Docs)

US: Republicans seek to derail plan restricting drug company deals (GenericsWeb)

US: WSJ stakes out position on patent settlements; Takes issue with the FTC’s ‘evangelical zeal’ (FDA Law Blog)

US: Are the rules a constraint to innovation, competition and a cause of adulterated products? (profitability through simplicity)

US: Yeda Appeals Board decision favoring Abbott in TBP-II interference (Holman’s Biotech IP Blog)

US: Jury finds Scruggs wilfully infringed Monsanto patents, awards at least $9 million in damages (Holman’s Biotech IP Blog)

US: Marcy Kaptur’s bill to create a compulsory license for patented seeds: the Seed Availability and Competition Act of 2009 (KEI)

US: Glaxosmithkline Biologicals seeks review of BPAI decision concerning isolated protein from B strain of N. meningitides: Glaxosmithkline Biologicals v Novartis Vaccines and Diagnostics et al (Patent Docs)

US: Delay attributable to withdrawn challenge to jurisdiction does not warrant extension of 30-month stay of FDA approval: Bayer Schering Pharma AG et al v Sandoz Inc et al (Docket Report)

Products

Actemra (Tocilizumab) – Netherlands: Contextual interpretation – Rejection of SPC application upheld (EPLAW)

Azilect (Rasagiline) – US: Watson confirms Azilect patent challenge (SmartBrief)

Favir (Famciclovir) – US: Novartis files patent infringement complaint against Watson following Para IV certification filing (Patent Docs)

Gemzar (Gemcitabine) – US: BIO weighs in with amicus brief in Sun Pharmaceuticals v Eli Lilly (Patent Docs)

Gemzar (Gemcitabine) – US: Hospira seeks declaratory judgment of non-infringement in relation to ANDA filing: Hospira v Eli Lilly & Co (Patent Docs)

Hectorol (Doxercalciferol) – US: Genzyme dismisses one inequitable conduct count in Hectorol suit: Bone Care International LLC v Pentech Pharmaceuticals Inc (Patent Docs)

Hectorol (Doxercalciferol) – US: Enough really is enough: Court strikes expert declaration: Bone Care International LLC v Pentech Pharmaceuticals Inc (Chicago Intellectual Property Law Blog)

Hepsera (Adefovir) – US: Gilead files patent infringement complaints against Sigmapharm in response to Para IV certification (Patent Docs)

Herceptin (Trastuzumab) – US: Glaxo fires latest shot in patent battle with Genentech over therapeutic molecule antibodies (Holman’s Biotech IP Blog)

Paxil (Paroxetine) – US: Mylan enjoins release of Apotex’s generic Paxil (Patent Docs)

Prezista (Darunavir) – US/Global: NIH becomes first patent holder to join UNITAID Medicines Patent Pool (IP Watch) (KEI)

Ryzolt (Tramadol) – US: Anchen seeks declaratory judgment of invalidity and non-infringement in relation to ANDA filing: Anchen v Labopharm et al (Patent Docs)

Seroquel (Quetiapine) – US: Astrazeneca files patent infringement complaint following Para IV challenge by Torrent (Patent Docs)

Taxotere (Docetaxel) – US: District Court finds Sanofi’s Taxotere invalid: Aventis v Hospira (Patent Docs)

Yasmin (Drospirenone, Ethinylestradiol) – US: ANDAs for generic Yasmin do not infringe Bayer patent: Bayer Schering Pharma AG et al v. Sandoz, Inc. et al (Docket Report)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: